Breakthrough Cuts Heart Disease by 25%
The Genetic Breakthrough Leading to Oral PCSK9 Inhibitors
Discover the decades-long genetic quest that identified PCSK9, unlocking a major biological switch for lowering dangerous LDL cholesterol. Learn how this knowledge led to injectable breakthroughs and, critically, the recent development of convenient oral treatments.
Short Summary
- Pinpoint the PCSK9 discovery that provided crystal-clear drug target validation for cholesterol reduction.
- Confirm that primary prevention trials successfully used PCSK9 inhibitors to prevent the first major cardiovascular events in high-risk patients.
- A new oral PCSK9 inhibitor now matches the LDL lowering efficacy of previous injectable therapies, promising wider accessibility.
This summary tracks the evolution from identifying the PCSK9 gene mutation in rare families to validating the treatment in large-scale prevention trials, culminating in more accessible delivery methods.
Unlock all features
FREE: Get instant access to 10 AI summaries, chats, or transcripts per day.
Unlock all features
FREE: Get instant access to 10 AI summaries, chats, or transcripts per day.
Unlock all features
FREE: Get instant access to 10 AI summaries, chats, or transcripts per day.
Unlock all features
FREE: Get instant access to 10 AI summaries, chats, or transcripts per day.
Unlock all features
FREE: Get instant access to 10 AI summaries, chats, or transcripts per day.
Related videos
They Had to Stop This Vitamin C Trial Early
Dr Brad Stanfield
17.6k views
Did One Tiny Tweak Just Solve Heart Disease?
Dr Brad Stanfield
25.6k views
What’s Causing Colon Cancer to Rise So Fast?
Dr Brad Stanfield
22.4k views
99% of Heart Attacks Had This Prior Warning
Dr Brad Stanfield
28.3k views
This $2 Remedy Beats Every Cold Medicine
Dr Brad Stanfield
50.4k views
Best Diet Confirmed by 5,248,916 Person-Year Study
Dr Brad Stanfield
23.3k views
The Truth about Saturated Fat and Heart Disease
Dr Brad Stanfield
18.5k views
Blood Pressure Targets Just Changed
Dr Brad Stanfield
194.3k views
The Best Diet to CRUSH Visceral Fat
Dr Brad Stanfield
45.4k views
“Current Evidence Does NOT Support Zone 2 Training”
Dr Brad Stanfield
93.6k views
Top Comments (10)
This is me, first heart attack age 35, second at age 38, another Angio at 42, Negative for the genetic markers & statin intolerant and then trials of evolocumab in 2016, still here 9 years after starting Repatha (evolocumab) and my LDL levels are awesome, it's been a real life saver and I'd never of been around long enough to see my daughter grow up. Thanks to everyone involved around the world.
You're setting a high bar for Primary care medicine. Rock on!
Fantastic information, skillfully presented. Thank you.
I'm so excited for enlicitide. Hopefully since it's not a mab and doesn't require an expensive delivery system it will be much cheaper than current PCSK9 inhibitors.
You do a great job communicating the story of how these studies happen. Thanks for your hard work
All 4 studies referenced in the video are linked in the video's description For extra insights + a free health checklist, sign up here 👉 https://drstanfield.com/pages/sign-up
Great summary, thanks!
Great info. Thanks.
Thanks Dr. Interesting information, lending itself to potentially having a positive impact for all of us, cardiovascular disease being debilitating and often deadly.
Brilliant overview of PCSK9’s discovery reshaping modern cholesterol therapeutics. 🔬
Unlock the Data Inside
Turn Videos into Knowledge
- Get FREE 10/day: transcripts, summaries, chats
- Chat with videos, export text & PDF
- $1 free API credit for RAG, chatbots & research
Free forever plan • All features unlocked
Top Comments (10)
This is me, first heart attack age 35, second at age 38, another Angio at 42, Negative for the genetic markers & statin intolerant and then trials of evolocumab in 2016, still here 9 years after starting Repatha (evolocumab) and my LDL levels are awesome, it's been a real life saver and I'd never of been around long enough to see my daughter grow up. Thanks to everyone involved around the world.
You're setting a high bar for Primary care medicine. Rock on!
Fantastic information, skillfully presented. Thank you.
I'm so excited for enlicitide. Hopefully since it's not a mab and doesn't require an expensive delivery system it will be much cheaper than current PCSK9 inhibitors.
You do a great job communicating the story of how these studies happen. Thanks for your hard work
All 4 studies referenced in the video are linked in the video's description For extra insights + a free health checklist, sign up here 👉 https://drstanfield.com/pages/sign-up
Great summary, thanks!
Great info. Thanks.
Thanks Dr. Interesting information, lending itself to potentially having a positive impact for all of us, cardiovascular disease being debilitating and often deadly.
Brilliant overview of PCSK9’s discovery reshaping modern cholesterol therapeutics. 🔬